Veterinary Intravenous (IV) Solutions Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031F

The Global Veterinary Intravenous (IV) Solutions Market is anticipated to expand from USD 1.51 billion in 2025 to USD 2.22 billion by 2031, reflecting a compound annual growth rate (CAGR) of 6.63%. These solutions consist of sterile fluids delivered parenterally to animals to ensure proper hydration, maintain electrolyte balance, provide vital nutrients, and facilitate medication delivery.

Growth in this sector is primarily driven by the worldwide increase in companion animal ownership and the growing trend of treating pets as family members, which significantly elevates the demand for sophisticated veterinary care. Additionally, the increasing prevalence of animal diseases that require intensive and supportive therapies plays a crucial role in propelling market advancement. Highlighting the scale of this industry, HealthforAnimals reported that the 20 leading animal health companies worldwide achieved a collective revenue of $38.6 billion in 2024.

Despite this positive trajectory, market growth faces potential setbacks due to the intricate challenges of global supply chain interruptions affecting pharmaceutical-grade raw materials and completed IV products. These logistical bottlenecks frequently lead to critical inventory shortages and drive up operational expenses for veterinary practices and animal hospitals around the world.

Market Driver

The escalating prevalence of diverse animal illnesses is a major catalyst for the Global Veterinary Intravenous (IV) Solutions Market, significantly boosting the requirement for diagnostic, therapeutic, and supportive interventions that rely on fluid therapy. With veterinary professionals increasingly treating intricate and chronic ailments, there is a surging need for IV fluids to manage rehydration, nutrient infusion, electrolyte stabilization, and drug delivery. Numerous common health issues require prolonged or recurring IV treatments for stabilizing acute episodes, aiding post-operative healing, or managing persistent diseases. Illustrating this point, 2024 data from Nationwide Pet Insurance revealed that chronic illnesses accounted for six of the top ten health concerns in dogs and seven of the top ten in cats, emphasizing the ongoing and rigorous medical needs of companion animals.

Concurrently, surging global pet ownership and the widespread cultural shift toward pet humanization heavily fuel the need for premium veterinary services, including intravenous therapies. As people increasingly regard their pets as cherished family members, they are much more inclined to fund advanced medical procedures, critical emergency care, and intricate surgeries. This deepened emotional connection directly results in heightened veterinary spending, which fosters the widespread use of thorough medical treatments. Underscoring this development, the American Pet Products Association noted that pet expenditures in the United States hit $158 billion in 2025, marking a 3.7% rise from the prior year. Such robust financial backing empowers veterinarians to implement a wider array of clinical therapies, including tailored IV solutions, a trend further validated by major industry entities like Zoetis, which recorded a total 2024 revenue of $9.3 billion.

Market Challenge

Interruptions within global supply networks pose a formidable barrier to the growth of the veterinary intravenous (IV) solutions sector. These logistical hurdles stem from difficulties in sourcing essential pharmaceutical-grade ingredients and maintaining the punctual distribution of completed IV products. Consequently, these supply bottlenecks lead to widespread inventory deficits in animal hospitals and veterinary clinics globally, forcing medical professionals to navigate the scarce availability of indispensable therapies. Additionally, the unpredictable nature of these distribution channels drives up the daily operational expenses for veterinary healthcare facilities.

The severity of these logistical obstacles is highlighted by the strategic initiatives implemented by leading professional organizations. In its 2025 Annual Report, the Federation of Veterinarians of Europe (FVE) noted that it addressed 60 formal consultations over the year, designating the secure supply of crucial medications as a primary policy objective. This dedicated involvement demonstrates how deeply supply chain inconsistencies affect the cost and availability of critical veterinary drugs, which ultimately disrupts the reliable delivery of animal healthcare and impedes the broader commercial expansion of the IV solutions market.

Market Trends

Technological progress in intravenous fluid administration and patient monitoring devices constitutes a major market trend, vastly improving the safety and accuracy of fluid therapy in veterinary medicine. These developments feature intelligent infusion pumps that guarantee precise delivery rates while seamlessly syncing with monitoring equipment to supply real-time physiological metrics, allowing practitioners to swiftly modify treatment plans. Such enhanced technological functionalities lead to superior clinical outcomes, particularly for critical patients where minor miscalculations in fluid dosage can result in severe complications. Demonstrating this shift, IDEXX Laboratories reported a 69% organic revenue surge for its CAG Diagnostics capital instruments in its Fourth Quarter and Full Year 2025 Results published on February 2, 2026, signaling a robust increase in veterinary investments for sophisticated diagnostic and critical care monitoring tools.

Another prominent trend is the widespread integration of balanced isotonic crystalloids, motivated by an advanced comprehension of animal physiology and the clinical need to prevent complications linked to unbalanced fluid types. Formulated to closely replicate the natural electrolyte makeup of blood plasma, these solutions are vital for sustaining proper acid-base equilibrium and mitigating risks like hyperchloremic acidosis. Their escalating use highlights a broader transition toward highly customized and sophisticated fluid administration strategies across routine and intensive veterinary environments. The critical need to refine baseline treatments is further evidenced by clinical management difficulties; for example, an April 14, 2025, article in Today's Veterinary Practice titled "Preventing Malnutrition in Critical Care Patients" noted that a study of 276 hospitalized dogs achieved a positive energy balance on merely 27% of treatment days, emphasizing the essential necessity for holistic and physiologically optimal patient interventions, including advanced fluid therapies.

Key Market Players

• Baxter International Inc.
• B. Braun SE
• ICU Medical, Inc.
• Fresenius Kabi AG
• Dechra Pharmaceuticals PLC
• Zoetis Inc.
• Elanco Animal Health Incorporated
• Virbac S.A.
• Vetoquinol S.A.
• Merck & Co., Inc.

Report Scope

In this report, the Global Veterinary Intravenous (IV) Solutions Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Veterinary Intravenous (IV) Solutions Market, By Product:

• Isotonic crystalloids
• Synthetic colloids
• Blood products
• Dextrose solutions
• Parenteral nutrition

Veterinary Intravenous (IV) Solutions Market, By Indication:

• Diabetic Ketoacidosis
• Pancreatitis
• Anthrax
• Chronic Kidney Disease
• Others

Veterinary Intravenous (IV) Solutions Market, By Animal type:

• Companion Animals
• Production Animals

Veterinary Intravenous (IV) Solutions Market, By End Use:

• Veterinary Hospitals
• Research Institutes
• Others

Veterinary Intravenous (IV) Solutions Market, By Region:

• North America
• Europe
• Asia Pacific
• South America
• Middle East & Africa

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Veterinary Intravenous (IV) Solutions Market.

Available Customizations

With the given market data, the publisher offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

This product will be delivered within 1-3 business days.